多不饱和脂肪酸与肌萎缩侧索硬化患者临床进展的关联:EMPOWER试验的事后分析
该研究纳入EMPOWER临床试验中449例有基线血浆样本的肌萎缩侧索硬化患者,分析血浆多不饱和脂肪酸水平与死亡风险及功能下降的关系。结果显示,较高的α-亚麻酸水平与较低的死亡风险(最高vs最低四分位HR 0.50,95%CI 0.29-0.86)和较高的联合秩检验评分(每增加1个标准差差异10.7,95%CI 0.2-21.1)相关,提示功能下降较慢。
要点
- 在449例肌萎缩侧索硬化患者中,较高血浆α-亚麻酸水平与较低死亡风险相关(最高vs最低四分位HR 0.50,95%CI 0.29-0.86)。
- 较高α-亚麻酸水平与较高的联合秩检验评分相关(每增加1个标准差差异10.7,95%CI 0.2-21.1),提示功能下降较慢。
- 较高的n-3脂肪酸二十碳五烯酸和n-6脂肪酸亚油酸水平与随访期间较低的死亡风险相关。
核心结论
- 在肌萎缩侧索硬化患者中,较高的α-亚麻酸水平与较长的生存时间和较慢的功能下降相关,作者认为α-亚麻酸可能对疾病进展有有利影响。
研究设计与样本
- EMPOWER临床试验的事后分析,纳入随机化时采集了可用于脂肪酸分析血浆样本的449例参与者,使用气相色谱法测定血浆脂肪酸。
主要发现
- 449例参与者基线平均(标准差)年龄为57.5(10.7)岁,293例(65.3%)为男性,随访期间126例(28.1%)死亡。
- 较高的α-亚麻酸水平与较低的死亡风险相关(最高vs最低四分位,年龄和性别校正HR 0.50,95%CI 0.29-0.86,p-trend=0.041)。
- 较高的α-亚麻酸水平与较高的联合秩检验评分相关(每增加1个标准差评分差异10.7,95%CI 0.2-21.1,p=0.045),与功能下降较慢一致。
- 在进一步校正体重指数、种族/民族、症状持续时间、起病部位、利鲁唑使用、ALS家族史、预测直立慢肺活量及治疗组后,估计值保持相似。
- 较高的n-3脂肪酸二十碳五烯酸和n-6脂肪酸亚油酸水平与随访期间较低的死亡风险相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Polyunsaturated fatty acids (PUFAs) have neuroprotective and anti-inflammatory effects and could be beneficial in amyotrophic lateral sclerosis (ALS). Higher dietary intake and plasma levels of PUFAs, in particular alpha-linolenic acid (ALA), have been associated with a lower risk of ALS in large epidemiologic cohort studies, but data on disease progression in patients with ALS are sparse. We examined whether plasma levels of ALA and other PUFAs contributed to predicting survival time and functional decline in patients with ALS. METHODS: We conducted a study among participants in the EMPOWER clinical trial who had plasma samples collected at the time of randomization that were available for fatty acid analyses. Plasma fatty acids were measured using gas chromatography. We used Cox proportional hazards models and linear regression to evaluate the association of individual fatty acids with risk of death and joint rank test score of functional decline and survival. RESULTS: Fatty acid analyses were conducted in 449 participants. The mean (SD) age of these participants at baseline was 57.5 (10.7) years, and 293 (65.3%) were men; 126 (28.1%) died during follow-up. Higher ALA levels were associated with lower risk of death (age-adjusted and sex-adjusted hazard ratio comparing highest vs lowest quartile 0.50, 95% CI 0.29-0.86, p-trend = 0.041) and higher joint rank test score (difference in score according to 1 SD increase 10.7, 95% CI 0.2-21.1, p = 0.045), consistent with a slower functional decline. The estimates remained similar in analyses adjusted for body mass index, race/ethnicity, symptom duration, site of onset, riluzole use, family history of ALS, predicted upright slow vital capacity, and treatment group. Higher levels of the n-3 fatty acid eicosapentaenoic acid and the n-6 fatty acid linoleic acid were associated with a lower risk of death during follow-up. DISCUSSION: Higher levels of ALA were associated with longer survival and slower functional decline in patients with ALS. These results suggest that ALA may have a favorable effect on disease progression in patients with ALS.
引用
- Bjornevik K, Cortese M, Furtado JD, et al. Association of Polyunsaturated Fatty Acids and Clinical Progression in Patients With ALS: Post Hoc Analysis of the EMPOWER Trial. Neurology. 2023. PMID: 37344230. doi:10.1212/WNL.0000000000207485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。